\nThe FDA mesh notification and its implications as well as lessons learned along the way from the use of transvaginal mesh will be reviewed. Given the current climate and the fact that FDA mandated studies will not yield results for a number of years recommendations for rational transvaginal mesh use will be reviewed.
\nWith an increase in the number of laparascopic/robotic assisted abdominal sacrocolpopexies it is critical to define which patients are and are not good candidates for this procedure. And even for those that are good candidates – does this approach always make sense? Recommendations in this regard will be reviewed.
\nFinally, the future of new prostheses in regard to new polymers, biomaterials, coating, concepts on biocompatibility and the basic science related to mesh extrusion/perforation will be reviewed.
\nWhere is the future of POP repair headed? We will attempt to illuminate the road ahead.